Premenstrual Syndromes : PMS and PMDD - Rutuja :: The site ...

135. Facchinetti F, Genazzani AD, Martignoni E et al. Neuroendocrine
changes in luteal function in patients with premenstrual syndrome.
J Clin Endocrinol Metab 1993; 76:1123–7.
136. Backstrom T, Aakvaag A. Plasma prolactin and testosterone
during the luteal phase in women with premenstrual tension syndrome.
Psychoneuroendocrinology 1981; 6:245–51.
137. Eriksson E, Sundblad C, Lisjo P et al. Serum levels of androgens
are higher in women with premenstrual irritability and dysphoria
than in controls. Psychoneuroendocrinology 1992; 17:195–204.
138. Bloch M, Schmidt PJ, Su T-P et al. Pituitary–adrenal hormones
and testosterone across the menstrual cycle in women with
premenstrual syndrome and controls. Biol Psychiatry 1998;
43:897–903.
139. Backstrom T, Wide L, Sodergard R et al. FSH, LH, TeBG-capacity,
estrogen and progesterone in women with premenstrual tension
during the luteal phase. J Steroid Biochem 1976; 7:473–6.
140. Backstrom T, Smith S, Lothian H et al. Prolonged follicular
phase and depressed gonadotropins following hysterectomy and
corpus lute-ectomy in women with premenstrual tension syndrome.
Clin Endocrinol 1985; 22:723–32.
141. Hammarback S, Damber J-E, Backstrom T. Relationship between
symptom severity and hormone changes in women with premenstrual
syndrome. J Clin Endocrinol Metab 1989; 68:125–30.
142. Schechter D, Strasser TJ, Endicott J et al. Role of ovarian
steroids in modulating mood in premenstrual syndrome. Abstr
Soc Biol Psych 51st Annu Meeting 1996; 646.
143. Halbreich U, Endicott J, Goldstein S et al. Premenstrual changes
and changes in gonadal hormones. Acta Psychiatr Scand 1986;
74:576–86.
144. Smith SS, Gong QH, Li X et al. Withdrawal from 3�-OH-5�pregnan-20-one
using a pseudopregnancy model alters the kinetics
of hippocampal GABA A -gated current and increases the
GABA A receptor �4 subunit in association with increased anxiety.
J Neurosci 1998; 18:5275–84.
145. Bitran D, Purdy RH, Kellogg CK. Anxiolytic effect of progesterone
is associated with increases in cortical allopregnanolone
and GABA A receptor function. Pharmacol Biochem Behav 1993;
45:423–8.
146. Bitran D, Hilvers RJ, Kellogg CK. Anxiolytic effects of 3�-hydroxy-
5a[�]-pregnan-20-one: endogenous metabolites of progesterone
that are active at the GABA A receptor. Brain Res 1991; 561:157–61.
147. Wieland S, Lan NC, Mirasedeghi S et al. Anxiolytic activity of
the progesterone metabolite 5�-pregnan-3�-ol-20-one. Brain
Res 1991; 565:263–8.
148. Purdy RH, Morrow AL, Moore PH Jr et al. Stress-induced elevations
of gamma-aminobutyric acid type A receptor-active steroids
in the rat brain. Proc Natl Acad Sci USA 1991; 88:4553–7.
149. Ströhle A, Romeo E, Hermann B et al. Concentrations of 3�reduced
neuroactive steroids and their precursors in plasma of
patients with major depression and after clinical recovery. Biol
Psychiatry 1999; 45:274–7.
150. Romeo E, Brancati A, de Lorenzo A et al. Marked decrease of
plasma neuroactive steroids during alcohol withdrawal. Clin
Neuropharmacol 1996; 19:366–9.
151. Romeo E, Strohle A, Spalletta G et al. Effects of antidepressant
treatment on neuroactive steroids in major depression. Am J
Psychiatry 1998; 155:910–13.
152. Uzunova V, Sheline Y, Davis JM et al. Increase in the cerebrospinal
fluid content of neurosteroids in patients with unipolar
major depression who are receiving fluoxetine or fluvoxamine.
Proc Natl Acad Sci USA 1998; 95:3239–44.
153. Griffin LD, Mellon SH. Selective serotonin reuptake inhibitors
directly alter activity of neurosteroidogenic enzymes. Proc Natl
Acad Sci USA 1999; 96:13512–17.
154. Sundstrom I, Andersson A, Nyberg S et al. Patients with premenstrual
syndrome have a different sensitivity to a neuroactive
PATHOPHYSIOLOGY I: ROLE OF OVARIAN STEROIDS 97
steroid during the menstrual cycle compared to control subjects.
Neuroendocrinology 1998; 67:126–38.
155. Sundstrom I, Nyberg S, Backstrom T. Patients with premenstrual
syndrome have reduced sensitivity to midazolam compared to
control subjects. Neuropsychopharmacology 1997; 17:370–81.
156. Rapkin AJ, Morgan M, Goldman L et al. Progesterone metabolite
allopregnanolone in women with premenstrual syndrome.
Obstet Gynecol 1997; 90:709–14.
157. Schmidt PJ, Purdy RH, Moore PH Jr et al. Circulating levels of
anxiolytic steroids in the luteal phase in women with premenstrual
syndrome and in control subjects. J Clin Endocrinol Metab
1994; 79:1256–60.
158. Sundstrom I, Backstrom T. Citalopram increases pregnanolone
sensitivity in patients with premenstrual syndrome: an open trial.
Psychoneuroendocrinology 1998; 23:73–88.
159. Rubinow DR, Schmidt PJ. The neuroendocrinology of menstrual
cycle mood disorders. Ann NY Acad Sci 1995; 771:648–59.
160. Redei E, Freeman EW. Preliminary evidence for plasma adrenocorticotropin
levels as biological correlates of premenstrual
symptoms. Acta Endocrinol 1993; 128:536–42.
161. Rosenstein DL, Kalogeras KT, Kalafut M et al. Peripheral measures
of arginine vasopressin, atrial natriuretic peptide and
adrenocorticotropic hormone in premenstrual syndrome.
Psychoneuroendocrinology 1996; 21:347–59.
162. Schmidt PJ, Grover GN, Roy-Byrne PP et al. Thyroid function in
women with premenstrual syndrome. J Clin Endocrinol Metab
1993; 76:671–4.
163. Facchinetti F, Martignoni E, Petraglia F et al. Premenstrual fall
of plasma �-endorphin in patients with premenstrual syndrome.
Fertil Steril 1987; 47:570–3.
164. Chuong CJ, Coulam CB, Kao PC et al. Neuropeptide levels in
premenstrual syndrome. Fertil Steril 1985; 44:760–5.
165. Taylor DL, Mathew RJ, Ho BT et al. Serotonin levels and platelet
uptake during premenstrual tension. Neuropsychobiology 1984;
12:16–18.
166. Ashby CR Jr, Carr LA, Cook CL et al. Alteration of platelet serotonergic
mechanisms and monoamine oxidase activity in premenstrual
syndrome. Biol Psychiatry 1988; 24:225–33.
167. Malmgren R, Collins A, Nilsson CG. Platelet serotonin uptake
and effects of vitamin B 6 -treatment in premenstrual tension.
Neuropsychobiology 1987; 18:83–8.
168. Veeninga AT, Westenberg HGM. Serotonergic function and late
luteal phase dysphoric disorder. Psychopharmacology 1992;
108:153–8.
169. Tulenheimo A, Laatikainen T, Salminen K. Plasma �-endorphin
immunoreactivity in premenstrual tension. Br J Obstet Gynaecol
1987; 94:26–9.
170. Hamilton JA, Gallant S. Premenstrual symptom changes and
plasma �-endorphin/�-lipotropin throughout the menstrual cycle.
Psychoneuroendocrinology 1988; 13:505–14.
171. Eriksson E, Alling C, Andersch B et al. Cerebrospinal fluid levels
of monoamine metabolites: a preliminary study of their relation
to menstrual cycle phase, sex steroids, and pituitary hormones in
healthy women and in women with premenstrual syndrome.
Neuropsychopharmacology 1994; 11:201–13.
172. Parry BL, Gerner RH, Wilkins JN et al. CSF and endocrine
studies of premenstrual syndrome. Neuropsychopharmacology
1991; 5:127–37.
173. McNeilly AS, Hagen C. Prolactin, TSH, LH and FSH responses
to a combined LHRH/TRH test at different stages of the menstrual
cycle. Clin Endocrinol 1974; 3:427–35.
174. Facchinetti F, Genazzani AD, Martignoni E et al. Neuroendocrine
correlates of premenstrual syndrome: changes in the pulsatile pattern
of plasma LH. Psychoneuroendocrinology 1990; 15:269–77.
175. Reame NE, Marshall JC, Kelch RP. Pulsatile LH secretion in
women with premenstrual syndrome (PMS): evidence for normal